Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer

Table 1

Characters of included studies.

First author	Year	Country	Method	Stage	Therapy regimen	Chemotherapy course	ERCC1 positive		ERCC1 negative		NOS score
							Response	No response	Response	No response
Lee	2009	Korea	IHC	IIIB-IV	Platinum-based	≥2	11	17	7	15	8
Ota	2009	Japan	IHC	IV	Platinum-based	≥2	26	74	15	41	8
Azuma	2009	Japan	IHC	IB-IIIB	Cisplatin-based	≥2	6	10	15	3	8
Wang	2009	China	IHC	IIIB-IV	Cisplatin-based	≥2	12	13	17	11	7
Shan	2009	China	IHC	IIIB-IV	Platinum-based	≥2	7	22	33	19	7
Wang	2009	China	IHC	III	Cisplatin-based	≥2	3	11	9	4	6
Wang	2010	China	IHC	IIIB-IV	Platinum-based	≥2	14	29	44	37	8
Li	2010	China	IHC	IIIB-IV	Cisplatin-based	≥2	3	30	11	27	7
Yang	2011	China	IHC	IIIB-IV	Cisplatin-based	≥2	4	16	13	14	7
Vassalou	2013	Greece	IHC	IIIB-IV	Platinum-based	≥2	13	42	14	25	8
Fumie	2013	Australia	IHC	III-IV	Platinum-based	≥2	5	23	8	15	8
Gao	2013	China	IHC	IIIA-IV	Platinum-based	≥2	21	54	19	53	7
Han	2017	Korea	IHC	IIIB-IV	Platinum-based	≥2	50	127	26	76	8
Honma	2018	Brasil	IHC	III-IV	Platinum-based	≥2	5	9	13	19	8